Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04984291

Zimmer Biomet Shoulder Arthroplasty PMCF

Zimmer Biomet Shoulder Arthroplasty Long-term Post Market Clinical Follow-up Study

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
584 (estimated)
Sponsor
Zimmer Biomet · Industry
Sex
All
Age
20 Years
Healthy volunteers
Not accepted

Summary

The objectives of this study are to confirm the safety, performance, and clinical benefits of Zimmer Biomet Shoulder Arthroplasty Systems and its instrumentation in primary or revision shoulder arthroplasty. These objectives will be assessed using standard scoring systems, radiographic evidence, and adverse event records. Safety of the system will be assessed by monitoring the frequency an incidence of adverse events.

Detailed description

The primary endpoint is defined as survival of the implant at 10 years, which is based on removal or intended removal of at least 1-study implant component and will be determined by using the Kaplan Meier method. The safety of the system will be assessed by monitoring the frequency and incidence of adverse events. Separate analysis will be done for each arm of the study. The secondary endpoint is represented by the performance and clinical benefits of Zimmer Biomet Shoulder Arthroplasty Systems and its instrumentation after 2 years, which will be assessed by the American Shoulder and Elbow Surgeons (ASES) shoulder score. The secondary endpoint evaluation will also assess the overall pain, functional performance, quality of life and radiographic parameters of all enrolled study subjects.

Conditions

Interventions

TypeNameDescription
DEVICEAlliance GlenoidAlliance Glenoid used in Primary or Revision Total Shoulder Arthroplasty
DEVICEIdentity StemIdentity Shoulder System is intended to be used in anatomic total shoulder arthroplasty, shoulder hemi-arthroplasty, or total reverse shoulder arthroplasty in both Primary or Revision Total Shoulder Arthroplasty

Timeline

Start date
2021-07-28
Primary completion
2033-08-15
Completion
2033-08-15
First posted
2021-07-30
Last updated
2025-10-29

Locations

17 sites across 3 countries: United States, Japan, New Zealand

Regulatory

Source: ClinicalTrials.gov record NCT04984291. Inclusion in this directory is not an endorsement.